1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
660E90611D60FD18E85257DE70074DEC9
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/big-data-in-pharma-information-type-&-sources-for-big-data-utilization-across-commercial-functions?opendocument
18
19opendocument
2054.226.175.101
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Market Research, Analytics and Forecasting Analytics

Big Data in Pharma: Information Type & Sources for Big Data Utilization Across Commercial Functions

ID: 5349


Features:

12 Info Graphics

10 Data Graphics

150+ Metrics

4 Narratives


Pages/Slides: 29


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Big Data in Pharma: Information Type & Sources for Big Data Utilization Across Commercial Functions"


STUDY OVERVIEW

The rapid evolution of Big Data is generating greater insights for commercial decisions within the biopharmaceutical industry. The inherent costs and challenges that come with harnessing large sets of information have caused the pharmaceutical sector to embrace Big Data analytics slower than other industries.

Identifying the most useful types of data and sources of data is an important initial step to realizing the huge potential that Big Data holds for commercial functions within pharma. It is also important to understand what internal and external groups value commercial Big Data analyses.

Best Practices, LLC undertook this study to probe current trends and best practices in commercial functions utilizing Big Data. The study offers key benchmarks around what types of data organizations are using most frequently as well as the data sources they find most useful. Also, the research examines which internal and external groups most value Big Data analyses and which are the most frequent requestors of such information.

KEY TOPICS

  • Defining Big Data
  • Data Types and Sources
  • Data Producers, Dissemination & Requestors

SAMPLE KEY METRICS
  • Value of listed types of transactional data sources
  • Value of listed types of reported/survey data sources
  • Value of listed types of online data sources
  • Value of listed types of scientific/clinical data sources
  • Value of listed types of machine-generated data
  • Value of listed types of data producers
  • The most impacted target audiences for data analysis
  • Most common ways for disseminating real world data analysis
  • Most common requestors of data analysis

SAMPLE KEY FINDING
  • Commercial Payers and internal company sources were the only types of data producers a majority of partners rated as highly valuable. A majority of the commercial segment also rated health systems as highly valuable.
  • Internal Commercial, Medical and Development functions were rated by a majority of respondents as the most impactful targets for data analysis presentations. A majority partners also said these internal groups were also the most frequent requestors of presentations.
METHODOLOGY

Twelve analytics, marketing and HEOR leaders from 12 different companies participated in this study. Participants were recruited because of their presumed investment in Big Data analytics.

Industries Profiled:
Pharmaceutical; Biotech; Chemical; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Novartis; Purdue Pharma; Genentech; AstraZeneca; Baxter International; GlaxoSmithKline ; Merck; Sanofi; Boehringer Ingelheim; Daiichi Sankyo; Pfizer; Teva Pharmaceutical Industries Ltd


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.